New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 30, 2013
10:55 EDTFDX, FDX, LLY, LLYSenate Finance Committee to hold a hearing
The Committee holds a hearing entitled, "Transatlantic Trade and Investment Partnership: Achieving the Potential". Participants include Executive Vice President Ducker of FedEx (FDX) and Senior Vice President Ricks of Eli Lilly (LLY) at the hearing being held on October 30 at 11 am. Webcast Link
News For FDX;LLY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
March 18, 2015
09:09 EDTFDXFedEx CFO says 'not ruling out' larger buybacks, currently buying 'steadily'
FedEx CFO Alan Graf said on the company's Q3 call, in response to a question about the company's balance sheet and taking on debt, that he "couldn't help" himself on taking on more debt than needed for Genco since "rates were so good" that FedEx could take advantage of what is in a sense "essentially free equity." Graf added that he is "not ruling out" further, larger buybacks, but at the moment FedEx is "steadily" buying back shares to prevent dilution.
09:03 EDTFDXFedEx says 400K share bought back during Q3
FedEx noted on its Q3 call that it did continue its stock buyback during the quarter and bought 400,000 shares back and that it plans to continue to buyback shares to prevent dilution from compensation programs. The company said its capital plan "remains steady as she goes, with expansion at Ground continuing. Ground's "substantial" CapEx is needed to continue to build automated hubs and satellites to handle the additional traffic that the company is expecting, FedEx executives noted.
08:57 EDTFDXFedEx says too early to talk about significant shifts in trade due to dollar
Subscribe for More Information
08:54 EDTFDXFedEx CFO says company projecting 'record' earnings again for FY16
Subscribe for More Information
08:40 EDTFDXFedEx sees U.S. GDP to grow 3.1% in 2015, 2016
Subscribe for More Information
07:46 EDTLLYLilly Roche would have upbeat read through from strong BIIB data, says Bernstein
Bernstein notes that the data for Biogen's (BIIB) Alzheimer's treatment, due to be released on Friday, is widely expected to be positive. The firm thinks that positive data would boost the outlook for similar Alzheimer's drugs being developed by Eli Lilly (LLY) and Roche (RHHBY), since consensus estimates for those drugs are low. The firm keeps Outperform ratings on Eli Lilly and Roche.
07:36 EDTFDXFedEx says Ground average daily volume grew 7% in Q3
Subscribe for More Information
07:35 EDTFDXFedEx says expects to deliver 'record' Q4, FY earnings
Subscribe for More Information
07:35 EDTFDXFedEx says share repurchases had 11c y/y positive impact on Q3 EPS
07:33 EDTFDXFedEx CEO says company had 'very successful' peak season
Subscribe for More Information
07:32 EDTFDXFedEx reports Q3 FedEx Express segment revenue $6.66B
Subscribe for More Information
07:31 EDTFDXFedEx sees FY15 EPS $8.80-$8.95, consensus $8.87
Subscribe for More Information
07:30 EDTFDXFedEx reports Q3 EPS $2.01, consensus $1.87
Reports Q3 revenue $11.7B, consensus $11.79B.
March 17, 2015
15:18 EDTFDXNotable companies reporting before tomorrow's open
Subscribe for More Information
14:38 EDTFDXFedEx technical comments ahead of earnings
The shares have been trading in a range largely bound by $170 at the low and $180 at the high since December of last year. So well-defined is the range that the 50-day moving average has gone flat, neatly bisecting the range at $174.63. These bounds may help us better understand where the shares may move following results. A breakout above $180 on strong news or outlook would resolve this range bullishly. The life high at $183.51 would very likely be tested, opening up a run to the $185 to $190 area. When ranges resolve, they tend to exhibit strong price reactions which could easily exceed the reaction expected by straddle pricing. On neutral news, the stock may fall near the 50-day moving average. If the news is a bearish surprise, we could expect the low of the range to be tested at the $170 area. It would take a break below that range low to turn the trend to bearish. Next support in that event would be at $167.62.
14:28 EDTFDXFedEx March 177 straddle priced for 3.6% movement into Q3
Subscribe for More Information
08:34 EDTFDXFedEx March volatility elevated into Q3 and outlook
Subscribe for More Information
March 16, 2015
07:27 EDTLLYBiodel BIOD-961 Phase 1 clinical trial meets primary efficacy endpoint
Biodel (BIOD) announced positive preliminary results from Study 6-101, a Phase 1 clinical trial comparing Biodel's lyophilized glucagon formulation BIOD-961, designed for use in a proprietary Glucagon Emergency Management, or GEM, auto-reconstitution device, to Eli Lilly's (LLY) Glucagon Emergency Rescue Kit and Novo Nordisk's GlucaGen HypoKit, which are marketed for the treatment of severe hypoglycemia. Study 6-101 was a randomized, single-center, double blind, six-period cross over study in 15 healthy volunteers who received each glucagon administered subcutaneously, or SC, and intramuscularly, or IM, in a randomized treatment sequence. The objectives of the study were to compare the pharmacokinetic, or PK, profiles, the pharmacodynamic, or PD, glucose, responses, and the PK/PD relationships of IM and SC dosing, as well as to assess safety profiles of the three test glucagons. Study 6-101 was a Phase 1 randomized, single-center, double blind, six-period cross over study designed to evaluate the PK and PD profiles of BIOD-961 compared to marketed glucagon formulations manufactured by Eli Lilly and Novo Nordisk. BIOD-961 is a lyophilized glucagon formulation designed for use in the GEM auto-reconstitution device. On six separate dosing days, each subject received 1 mg of one of the test glucagons delivered either SC or IM. Fifteen normal, healthy subjects were randomized into the study and ten completed all dosings. The objectives of the study were to compare the PK profiles, the PD responses, and the PK/PD relationships of IM and SC dosing, as well as to assess safety profiles of the three test glucagons. These data will facilitate selection of an appropriate marketed glucagon to use as a comparator in the planned pivotal study, in which the primary efficacy endpoint for approval is to demonstrate PK and PD bioequivalence of BIOD-961 to one of the marketed comparators.
March 12, 2015
14:34 EDTFDXFedEx March volatility elevated into Q3 and outlook
FedEx March call option implied volatility is at 32, April is at 23, July and October is at 19; compared to its 26-week average of 22 according to Track Data, suggesting large near term price movement into the expected release of Q3 results before the market open on March 18.
13:01 EDTLLYEli Lilly management to meet with SunTrust
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use